The Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2015

Citation, commencement and interpretation

1.—(1) These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2015 and come into operation on 5th March 2015.

(2) The Interpretation Act (Northern Ireland) 1954(1) shall apply to these Regulations as it applies to an Act of the Northern Ireland Assembly.

Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002

2.  The Misuse of Drugs Regulations (Northern Ireland) 2002(2) are amended as follows

3.  In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of Regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

(a) after “Tenocyclidine” insert—

“(6aR,9R-4-acetyl-N, N-diethyl-7-methyl-4, 6, 6a, 7, 8, 9-hexahydroindolo[4, 3-fg]quinoline-9-carboxamide (ALD-52”;

(b) after “4-Bromo-2,5-dimethoxy-a-methylphenethylamine” insert—

“3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)

(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)

(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)

(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)”

(c) after “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol” insert—

“2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg]quinolin-9-yl}methanone (LSZ)”.

4.  For paragraph 1(b) of Schedule 1, substitute—

“(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

(i) by substitution at the nitrogen atom of the side chain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent”.

5.  In paragraph 1 of Schedule 2 (which specifies controlled drugs subject to the requirements of Regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27) after “Hydromorphone” insert—

“4-Hydroxy-n-butyric acid”.

6.  In paragraph 1 of Part 1 of Schedule 4 (controlled drugs subject to the requirements of Regulations 22, 23, 26 and 27) omit “4-Hydroxy-n-butyric acid”(3).

Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 12th February 2015

Dr Paddy Woods

A senior officer of the

Department of Health, Social Services and Public Safety